Literature DB >> 17701832

The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.

G I Somers1, A J Harris, M K Bayliss, J B Houston.   

Abstract

The metabolism of the structurally related 5HT3 antagonists ondansetron, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes. The profiles of phase I metabolites were similar in human hepatocytes and microsomes. The metabolites of all three compounds produced in rat, dog and human microsomes and hepatocytes were similar to those seen in vivo, with the major routes of metabolism being N-dealkylation and/or hydroxylation. There was more extensive metabolic processing in hepatocytes than in microsomes; however, sequential metabolism was less extensive in vitro compared with in vivo. The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity. These data support the use of rat, dog and human hepatocytes for the prediction of in vivo metabolites of ondansetron, alosetron and GR87442.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701832     DOI: 10.1080/00498250701485575

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

2.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

3.  Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.

Authors:  Udoamaka Ezuruike; Mian Zhang; Amita Pansari; Mailys De Sousa Mendes; Xian Pan; Sibylle Neuhoff; Iain Gardner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-18

Review 4.  Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Authors:  Florian Klomp; Christoph Wenzel; Marek Drozdzik; Stefan Oswald
Journal:  Pharmaceutics       Date:  2020-12-11       Impact factor: 6.321

5.  5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders.

Authors:  Shvetank Bhatt; Thangaraj Devadoss; Santhepete Nanjundaiah Manjula; Jayaraman Rajangam
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 6.  Dealing with PET radiometabolites.

Authors:  Krishna Kanta Ghosh; Parasuraman Padmanabhan; Chang-Tong Yang; Sachin Mishra; Christer Halldin; Balázs Gulyás
Journal:  EJNMMI Res       Date:  2020-09-23       Impact factor: 3.138

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.